cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Minerva Neurosciences Inc
44 own
62 watching
Current Price
$2.52
$0.19
(8.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
13.46M
52-Week High
52-Week High
15.27
52-Week Low
52-Week Low
1.26
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
14.8675
iconMarket Capitalization13.46M
icon52-Week High15.27
icon52-Week Low1.26
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio14.8675
What does the Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Read More
How much money does Minerva Neurosciences Inc make?
News & Events about Minerva Neurosciences Inc.
Globe Newswire
1month ago
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on November 30...
PR Newswire
2 months ago
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates PR Newswire PALM BEACH, FL, Nov. 14, 2022 PALM BEACH, FL, Nov. 14, 2022...
Globe Newswire
2 months ago
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key ...
Globe Newswire
3 months ago
BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the company has received a refusal to file letter ...
Zolmax
5 months ago
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV Get Rating) in a research report report published on Thursday. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, HC Wainwright reduced their price objective on Minerva Neurosciences from $40...
Frequently Asked Questions
Frequently Asked Questions
What is Minerva Neurosciences Inc share price today?
plus_minus_icon
Can Indians buy Minerva Neurosciences Inc shares?
plus_minus_icon
How can I buy Minerva Neurosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Minerva Neurosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Minerva Neurosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Minerva Neurosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Minerva Neurosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Minerva Neurosciences Inc?
plus_minus_icon
What percentage is Minerva Neurosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Minerva Neurosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.52
$0.19
(8.15%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$29.88
$0.56 (1.91 %)
Omeros Corporation
Omeros Corporation
$3.15
$0.27 (9.38 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$38.34
$-0.84 (-2.14 %)
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
$1.18
$-0.06 (-4.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$29.88
$0.56 (1.91 %)
Omeros Corporation
Omeros Corporation
$3.15
$0.27 (9.38 %)
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
$38.34
$-0.84 (-2.14 %)
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
$1.18
$-0.06 (-4.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00